{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:10:30Z","timestamp":1792181430914,"version":"4.4.0"},"reference-count":49,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.13.04095","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:36:38Z","timestamp":1693510598000},"source":"Crossref","is-referenced-by-count":15,"title":["A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication"],"prefix":"10.7189","volume":"13","author":[{"given":"Yeo Jin","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South Korea"},{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, South Korea"},{"name":"Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ajou University Medical Hospital, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Ui","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyoung","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, South Korea"},{"name":"Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"key-10.7189\/jogh.13.04095-202308302247-R1","doi-asserted-by":"publisher","first-page":"104754","DOI":"10.1016\/j.compbiomed.2021.104754","article-title":"A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity.","volume":"136","author":"Safaei","year":"2021","journal-title":"Comput Biol Med"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R2","unstructured":"World Health Organization. Obesity and overweight. 2021. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed: 9 June 2021."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R3","unstructured":"Centers for Disease Control and Prevention. Adult obesity facts. 2022. Available: https:\/\/www.cdc.gov\/obesity\/data\/adult.html. Accessed: 2 May 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R4","doi-asserted-by":"publisher","first-page":"2042018820934955","DOI":"10.1177\/2042018820934955","article-title":"Adult obesity complications: challenges and clinical impact.","volume":"11","author":"Ansari","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R5","unstructured":"Centers for Disease Control and Prevention. Obesity and cancer. 2023. Available: https:\/\/www.cdc.gov\/cancer\/obesity\/index.htm. Accessed: 2 May 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R6","doi-asserted-by":"publisher","first-page":"e184587","DOI":"10.1001\/jamanetworkopen.2018.4587","article-title":"Association of obesity with mortality over 24 years of weight history: Findings from the Framingham heart study.","volume":"1","author":"Xu","year":"2018","journal-title":"JAMA Netw Open"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1467-789X.2001.00040.x","article-title":"Quality of life and obesity.","volume":"2","author":"Kolotkin","year":"2001","journal-title":"Obes Rev"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R8","doi-asserted-by":"publisher","first-page":"e0273553","DOI":"10.1371\/journal.pone.0273553","article-title":"Comorbidity and quality of life in obesity-a comparative study with the general population in Gothenburg, Sweden.","volume":"17","author":"Mejaddam","year":"2022","journal-title":"PLoS One"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R9","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.37765\/ajmc.2022.89292","article-title":"A review of current guidelines for the treatment of obesity.","volume":"28","author":"Cornier","year":"2022","journal-title":"Am J Manag Care"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R10","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society.","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges.","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5534\/wjmh.200010","article-title":"Anti-obesity drugs: Long-term efficacy and safety: An updated review.","volume":"39","author":"Tak","year":"2021","journal-title":"World J Mens Health"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R14","first-page":"771","article-title":"A review of pharmacovigilance.","volume":"63","author":"Campbell","year":"2014","journal-title":"West Indian Med J"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/ph14080783","article-title":"Comparative safety profiles of sedatives commonly used in clinical practice: A 10-year nationwide pharmacovigilance study in Korea.","volume":"14","author":"Choi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cts.12683","article-title":"The Advantages and Challenges of Using Real-World Data for Patient Care.","volume":"13","author":"Ho","year":"2020","journal-title":"Clin Transl Sci"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R17","unstructured":"USA Food & Drug Administration. Real-world evidence. 2023. Available: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed: 2 May 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cpt.2172","article-title":"A new era in pharmacovigilance: Toward real-world data and digital monitoring.","volume":"109","author":"Lavertu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R19","unstructured":"Strengthening the reporting of observational studies in epdiemiology (STROBE). What is STROBE? 2023. Available: https:\/\/www.strobe-statement.org\/. Accessed: 23 February 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.1796","article-title":"Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.","volume":"18","author":"Shin","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/pds.3715","article-title":"New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).","volume":"23","author":"Shin","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R23","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1007\/s00213-018-5079-1","article-title":"Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.","volume":"235","author":"Smith","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R24","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5414\/CP204180","article-title":"Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.","volume":"60","author":"Arguelles-Tello","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss.","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.21215\/kjfp.2020.10.2.77","article-title":"[Obesity treatment in ambulatory care focused on pharmacotherapy].","volume":"10","author":"Cho","year":"2020","journal-title":"Korean J Fam Pract"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3904\/kjm.2018.93.6.501","article-title":"[Recent advances in anti-obesity agents].","volume":"93","author":"Kim","year":"2018","journal-title":"Korean J Med"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R29","unstructured":"Uppsala Monitoring Center. The use of the WHO-UMC system for standardised case causality assessment. 2018. Available: https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf. Accessed: 18 December 2022."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R30","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharamceutical for human use. Post-approval safety data management: definitions and standard for expedited reporting E2D. 2003. Available: https:\/\/database.ich.org\/sites\/default\/files\/E2D_Guideline.pdf. Accessed: 18 December 2022."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting.","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations.","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R33","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/dom.14367","article-title":"Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.","volume":"23","author":"Suissa","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R34","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.22581","article-title":"Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015.","volume":"27","author":"Saxon","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4093\/dmj.2012.36.1.13","article-title":"Anti-obesity drugs: A review about their effects and safety.","volume":"36","author":"Kang","year":"2012","journal-title":"Diabetes Metab J"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R36","doi-asserted-by":"publisher","first-page":"e23780","DOI":"10.1097\/MD.0000000000023780","article-title":"Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.","volume":"100","author":"Park","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R37","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.3390\/ijerph17113926","article-title":"Gender differences in medication use: A drug utilization study based on real world data.","volume":"17","author":"Orlando","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R38","doi-asserted-by":"publisher","first-page":"e002378","DOI":"10.1136\/bmjopen-2012-002378","article-title":"Mia von E, Ulf B, Karin S-G. Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden.","volume":"3","author":"Loikas","year":"2013","journal-title":"BMJ Open"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/TP.0000000000002359","article-title":"Gender differences in medication adherence among adolescent and young adult kidney transplant recipients.","volume":"103","author":"Boucquemont","year":"2019","journal-title":"Transplantation"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2458-14-87","article-title":"The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study.","volume":"14","author":"Patterson","year":"2014","journal-title":"BMC Public Health"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/jpm12010005","article-title":"Fatal events associated with adverse drug reactions in the Korean national pharmacovigilance database.","volume":"12","author":"Jo","year":"2021","journal-title":"J Pers Med"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R42","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. 2023. Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists. Accessed 11 July 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IPRP.S105881","article-title":"Pharmacovigilance: pharmacists\u2019 perspective on spontaneous adverse drug reaction reporting.","volume":"6","author":"Hadi","year":"2017","journal-title":"Integr Pharm Res Pract"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000524995","article-title":"Use of fluoxetine to reduce weight in adults with overweight or obesity: Abridged republication of the Cochrane Systematic Review.","volume":"15","author":"Serralde-Zu\u00f1iga","year":"2022","journal-title":"Obes Facts"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clnesp.2020.03.008","article-title":"Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis.","volume":"37","author":"Talenezhad","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"key-10.7189\/jogh.13.04095-202308302247-R46","unstructured":"Korea Food & Drug Administration. [Witdrawal of obesity drug (sibutramine)]. 2010. Available: https:\/\/www.korea.kr\/briefing\/pressReleaseView.do?newsId=155692514#pressRelease. Accessed: 15 May 2023. Korean."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R47","unstructured":"USA Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. 2022. Available: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market. Accessed: 5 May 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R48","unstructured":"European Medicines Agency. Belviq: Withdrawal of the marketing authorsiation application. 2013. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/belviq. Accessed 23 May 2023."},{"key":"key-10.7189\/jogh.13.04095-202308302247-R49","unstructured":"European Medicines Agency. EMA recommends withdrawal of marketing authorisation for amfepramone medicines. 2022. Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-withdrawal-marketing-authorisation-amfepramone-medicines. Accessed:15 May 2023."}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2023\/jogh-13-04095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:36:43Z","timestamp":1693510603000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2023\/jogh-13-04095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7189\/jogh.13.04095","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"04095"}}